Iron overload decreases CaV1.3-dependent L-type Ca 2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 4, Issue 5, 2011, Pages 733-742

  Rose, Robert A ^a   Sellan, Michael ^a   Simpson, Jeremy A ^a   Izaddoustdar, Farzad ^a   Cifelli, Carlo ^a   Panama, Brian K ^a   Davis, Mark ^a   Zhao, Dongling ^a   Markhani, Moniba ^a   Murphy, Geoffrey G ^b   Striessnig, Joerg ^c   Liu, Peter P ^a   Heximer, Scott P ^a   Backx, Peter H ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Action potentials; Arrhythmias; Bradycardia; Calcium channels; Cardiac electrophysiology; Ion channels; Iron overload

Indexed keywords

CALCIUM CHANNEL L TYPE; IRON; CACNA1D PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CALCIUM CURRENT; CONTROLLED STUDY; ELECTRIC CONDUCTIVITY; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART CONDUCTION; HEART RATE; IRON OVERLOAD; ISOLATED HEART; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; SINUS NODE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENETICS; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION SYSTEM; MALE; METABOLISM; MOUSE MUTANT; MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ATRIAL FIBRILLATION; BRADYCARDIA; CALCIUM CHANNELS, L-TYPE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART CONDUCTION SYSTEM; HEART RATE; IRON; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MYOCYTES, CARDIAC; SINOATRIAL NODE;

EID: 84555208189     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.110.960401     Document Type: Article

References (46)

1. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209-221.
2. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698-705.
3. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther. 1994;8:101-110. (Pubitemid 24164805)
4. 2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84:349-364. (Pubitemid 43673610)
5. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97: 3411-3416.
6. Davis MJ, Wu X, Nurkiewicz TR, Kawasaki J, Gui P, Hill MA, Wilson E. Regulation of ion channels by protein tyrosine phosphorylation. Am J Physiol. 2001;281:H1835-H1862.
7. Lombardo T, Tamburino C, Bartoloni G, Morrone ML, Frontini V, Italia F, Cordaro S, Privitera A, Calvi V. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann Hematol. 1995;71: 135-141.
8. Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation. 1967;35:631-637.
9. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med. 1999;4:93-99. (Pubitemid 29290825)
10. Rosenqvist M, Hultcrantz R. Prevalence of a haemochromatosis among men with clinically significant bradyarrhythmias. Eur Heart J. 1989;10: 473-478. (Pubitemid 19169942)
11. Wang TL, Chen WJ, Liau CS, Lee YT. Sick sinus syndrome as the early manifestation of cardiac hemochromatosis. J Electrocardiol. 1994;27: 91-96.
12. Laurita KR, Chuck ET, Yang T, Dong WQ, Kuryshev YA, Brittenham GM, Rosenbaum DS, Brown AM. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med. 2003;142:83-89. (Pubitemid 37130040)
13. Obejero-Paz CA, Yang T, Dong WQ, Levy MN, Brittenham GM, Kuryshev YA, Brown AM. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med. 2003;141:121-130. (Pubitemid 36216565)
14. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-1194. (Pubitemid 37173704)
15. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol. 2002;93:746-751. (Pubitemid 34810241)
16. Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, Schiavone D, Piga A, Chiandussi L. Blood pressure and heart rate in young thalassemia major patients. Am J Hypertens. 1998;11:539-547. (Pubitemid 28270714)
17. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Ann Rev Neurosci. 2007;30:317-337. (Pubitemid 47224759)
18. Cardoso LM, Pedrosa ML, Silva ME, Moraes MF, Colombari E, Chianca DA Jr. Baroreflex function in conscious rats submitted to iron overload. Braz J Med Biol Res. 2005;38:205-214. (Pubitemid 40372596)
19. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993;73:197-227. (Pubitemid 23065438)
20. Mangoni ME, Nargeot J. Genesis and regulation of the heart automaticity. Physiol Rev. 2008;88:919-982.
21. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999; 100:675-683. (Pubitemid 29379759)
22. Kim E, Giri SN, Pessah IN. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol. 1995;130:57-66.
23. 2+- release channels of skeletal sarcoplasmic reticulum vesicles reconstituted in lipid bilayers. Arch Biochem Biophys. 1994;308:214-221.
24. Lesnefsky EJ, Ye J. Exogenous intracellular, but not extracellular, iron augments myocardial reperfusion injury. Am J Physiol. 1994;266: H384-H392. (Pubitemid 24104778)
25. Sellan M, Rose RA, Ciffeli C, Heximer SP, Backx PH. Chronic ironoverload causes sinus bradycardia by altering electrical activity in sinoatrial node myocytes. Biophys J. 2009;96:259a-260a.
26. Rose RA, Kabir MG, Backx PH. Altered heart rate and sinoatrial node function in mice lacking the cAMP regulator phosphoinositide 3-kinasegamma. Circ Res. 2007;101:1274-1282. (Pubitemid 350294644)
27. Rose RA, Lomax AE, Kondo CS, Anand-Srivastava MB, Giles WR. Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. Am J Physiol. 2004;286: H1970-H1977. (Pubitemid 38525488)
28. Cifelli C, Rose RA, Zhang H, Voigtlaender-Bolz J, Bolz SS, Backx PH, Heximer SP. RGS4 Regulates Parasympathetic signaling and heart rate control in the sinoatrial node. Circ Res. 2008;103:527-535.
29. Yang T, Brittenham GM, Dong WQ, Levy MN, Obejero-Paz CA, Kuryshev YA, Brown AM. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med. 2003;142:332-340. (Pubitemid 37487403)
30. Kardelen F, Tezcan G, Akcurin G, Ertug H, Yesilipek A. Heart rate variability in patients with thalassemia major. Pediatr Cardiol. 2008;29: 935-939.
31. 2+ channels in cardiac pacemaker activity. Proc Natl Acad Sci U S A. 2003;100:5543-5548. (Pubitemid 36542741)
32. Zhang Z, He Y, Tuteja D, Xu D, Timofeyev V, Zhang Q, Glatter KA, Xu Y, Shin HS, Low R, Chiamvimonvat N. Functional roles of Cav1.3(alpha1D) calcium channels in atria: insights gained from genetargeted null mutant mice. Circulation. 2005;112:1936-1944. (Pubitemid 41377411)
33. Zhang Z, Xu Y, Song H, Rodriguez J, Tuteja D, Namkung Y, Shin HS, Chiamvimonvat N. Functional roles of Ca(v) 1.3 (alpha(1D)) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ Res. 2002;90:981-987. (Pubitemid 34633864)
34. Zacharski LR, McKernan L, Metzger ME, Malone MG, Samnotra V, Bhargava A, Steiner PR, Rauwerdink CA, Ornstein DL, Cornell CJ. Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A. Haemophilia. 2010;16:726-730.
35. Matthes J, Yildirim L, Wietzorrek G, Reimer D, Striessnig J, Herzig S. Disturbed atrio-ventricular conduction and normal contractile function in isolated hearts from Cav1.3-knockout mice. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:554-562. (Pubitemid 38823987)
36. Stull LB, Hiranandani N, Kelley MA, Leppo MK, Marban E, Janssen PM. Murine strain differences in contractile function are temperature- and frequency-dependent. Pflugers Arch. 2006;452:140-145. (Pubitemid 44029838)
37. 2+ channels. Cell. 2000;102:89-97.
38. 2+ channel modifiers: possible implications in iron overload. Circ Res. 1999;84: 1302-1309. (Pubitemid 29270045)
39. Dobrzynski H, Boyett MR, Anderson RH. New insights into pacemaker activity: promoting understanding of sick sinus syndrome. Circulation. 2007;115:1921-1932. (Pubitemid 46598906)
40. Lei M, Zhang H, Grace AA, Huang CL. SCN5A and sinoatrial node pacemaker function. Cardiovasc Res. 2007;74:356-365. (Pubitemid 46711089)
41. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk betathalassemia. Blood. 2000;95:1229-1236. (Pubitemid 30099831)
42. 2+ channel KO mouse. Am J Physiol. 2008;295: H2017-H2024.
43. Qu Y, Baroudi G, Yue Y, Boutjdir M. Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmuneassociated sinus bradycardia. Circulation. 2005;111:3034-3041. (Pubitemid 40847779)
44. 2+ currents and human atrial fibrillation. Circ Res. 1999;85:428-436. (Pubitemid 29409619)
45. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512-525. (Pubitemid 27432738)
46. Gaborit N, Steenman M, Lamirault G, Le MN, Le BS, Lande G, Leger J, Charpentier F, Christ T, Dobrev D, Escande D, Nattel S, Demolombe S. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation. 2005;112:471-481. (Pubitemid 41060786)